---
document_datetime: 2025-12-29 08:01:46
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/zelboraf.html
document_name: zelboraf.html
version: success
processing_time: 0.133248
conversion_datetime: 2025-12-30 02:03:02.059055
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Zelboraf

[RSS](/en/individual-human-medicine.xml/65941)

##### Authorised

This medicine is authorised for use in the European Union

vemurafenib Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Zelboraf](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-77399)
- [More information on Zelboraf](#more-information-on-zelboraf-568)
- [More information on Zelboraf](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Zelboraf is a cancer medicine used to treat adults with melanoma (a type of skin cancer) that has spread to other parts of the body or cannot be surgically removed. Zelboraf is only for patients whose melanoma tumour cells have a specific mutation (genetic change) called 'BRAF V600'.

Zelboraf contains the active substance vemurafenib.

Expand section

Collapse section

## How is Zelboraf used?

Zelboraf can only be obtained with a prescription and treatment should be started and supervised by a specialist doctor experienced in treating cancer. Before starting treatment a test must be carried out to make sure that the patient's tumours have the BRAF V600 mutation.

Zelboraf is available as tablets (240 mg). The recommended dose is 960 mg (four tablets) twice daily. The first dose is taken in the morning and the second dose in the evening around 12 hours later. Each dose can be taken with or without food, but Zelboraf should be taken in the same way day-to-day.

Treatment should be continued until the disease worsens or the side effects become too severe.

For more information about using Zelboraf, see the package leaflet or contact your doctor or pharmacist.

## How does Zelboraf work?

The active substance in Zelboraf, vemurafenib, is an inhibitor of BRAF, a protein involved in stimulating cell division. In melanoma tumours with the BRAF V600 mutation, an abnormal form of BRAF is present which plays a role in the development of the cancer by allowing uncontrolled division of the tumour cells. By blocking the action of the abnormal BRAF, Zelboraf helps to slow down the growth and spread of the cancer.

## What benefits of Zelboraf have been shown in studies?

Zelboraf was compared with the cancer medicine dacarbazine in a main study involving 675 patients with melanoma containing the BRAF V600 mutation whose tumours had spread or could not be surgically removed. Patients were to receive either medicine until their disease got worse or their treatment became too toxic for them. The main measures of effectiveness were how long the patients lived (overall survival) and how long they lived without their disease getting worse (progression-free survival).

Zelboraf was shown to be effective at prolonging patients' lives and delaying the worsening of the disease. The study showed that patients taking Zelboraf lived on average for 13.2 months compared with 9.9 months for patients on dacarbazine, and it took on average 5.3 months for the disease to worsen in the Zelboraf group compared with 1.6 months in the dacarbazine group.

## What are the risks associated with Zelboraf?

The most common side effects with Zelboraf (which may affect more than 3 in 10 patients) include arthralgia (joint pain), tiredness, rash, photosensitivity reaction (sunburn-like reactions following exposure to light), nausea and vomiting (feeling sick and being sick), alopecia (hair loss), diarrhoea, headache, pruritus (itching), skin papilloma (warts) and hyperkeratosis (thickening and toughening of the skin). The most common serious side effects include another type of skin cancer called 'cutaneous squamous cell carcinoma', which is commonly treated by local surgery, keratoacanthoma (benign skin tumour), rash, arthralgia and change in liver test results (increased gamma-glutamyltransferase [GGT]).

For the full list of side effects and restrictions with Zelboraf, see the package leaflet.

## Why is Zelboraf authorised in the EU?

The European Medicines Agency decided that Zelboraf's benefits are greater than its risks and it can be authorised for use in the EU. The Agency noted that Zelboraf had been convincingly shown to improve overall survival and to delay the worsening of 'BRAF V600 positive' melanoma which has spread or cannot be surgically removed. With regard to its risks, in the main study around half of the patients taking Zelboraf experienced a severe side effect and about one fifth developed cutaneous squamous cell carcinoma. The Agency considered the side effects to be manageable and included recommendations for doctors to help reduce the risks in the product information.

## What measures are being taken to ensure the safe and effective use of Zelboraf?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zelboraf have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Zelboraf are continuously monitored. Side effects reported with Zelboraf are carefully evaluated and any necessary action taken to protect patients.

## Other information about Zelboraf

Zelboraf received a marketing authorisation valid throughout the EU on 17 February 2012.

Zelboraf : EPAR - Summary for the public

Reference Number: EMA/53181/2012

English (EN) (77.27 KB - PDF)

**First published:** 19/03/2012

**Last updated:** 12/04/2018

[View](/en/documents/overview/zelboraf-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-245)

български (BG) (105 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

12/04/2018

[View](/bg/documents/overview/zelboraf-epar-summary-public_bg.pdf)

español (ES) (77.05 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

12/04/2018

[View](/es/documents/overview/zelboraf-epar-summary-public_es.pdf)

čeština (CS) (102.17 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

12/04/2018

[View](/cs/documents/overview/zelboraf-epar-summary-public_cs.pdf)

dansk (DA) (74.84 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

12/04/2018

[View](/da/documents/overview/zelboraf-epar-summary-public_da.pdf)

Deutsch (DE) (57.24 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

12/04/2018

[View](/de/documents/overview/zelboraf-epar-summary-public_de.pdf)

eesti keel (ET) (75.2 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

12/04/2018

[View](/et/documents/overview/zelboraf-epar-summary-public_et.pdf)

ελληνικά (EL) (111.88 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

12/04/2018

[View](/el/documents/overview/zelboraf-epar-summary-public_el.pdf)

français (FR) (77.56 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

12/04/2018

[View](/fr/documents/overview/zelboraf-epar-summary-public_fr.pdf)

hrvatski (HR) (95.62 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

12/04/2018

[View](/hr/documents/overview/zelboraf-epar-summary-public_hr.pdf)

italiano (IT) (76.27 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

12/04/2018

[View](/it/documents/overview/zelboraf-epar-summary-public_it.pdf)

latviešu valoda (LV) (98.66 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

12/04/2018

[View](/lv/documents/overview/zelboraf-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (100.66 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

12/04/2018

[View](/lt/documents/overview/zelboraf-epar-summary-public_lt.pdf)

magyar (HU) (96.49 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

12/04/2018

[View](/hu/documents/overview/zelboraf-epar-summary-public_hu.pdf)

Malti (MT) (102.31 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

12/04/2018

[View](/mt/documents/overview/zelboraf-epar-summary-public_mt.pdf)

Nederlands (NL) (76.75 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

12/04/2018

[View](/nl/documents/overview/zelboraf-epar-summary-public_nl.pdf)

polski (PL) (101.2 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

12/04/2018

[View](/pl/documents/overview/zelboraf-epar-summary-public_pl.pdf)

português (PT) (77.06 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

12/04/2018

[View](/pt/documents/overview/zelboraf-epar-summary-public_pt.pdf)

română (RO) (99.84 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

12/04/2018

[View](/ro/documents/overview/zelboraf-epar-summary-public_ro.pdf)

slovenčina (SK) (100.93 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

12/04/2018

[View](/sk/documents/overview/zelboraf-epar-summary-public_sk.pdf)

slovenščina (SL) (96.35 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

12/04/2018

[View](/sl/documents/overview/zelboraf-epar-summary-public_sl.pdf)

Suomi (FI) (74.81 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

12/04/2018

[View](/fi/documents/overview/zelboraf-epar-summary-public_fi.pdf)

svenska (SV) (75.35 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

12/04/2018

[View](/sv/documents/overview/zelboraf-epar-summary-public_sv.pdf)

Zelboraf : EPAR - Risk-management-plan summary

English (EN) (93.54 KB - PDF)

**First published:** 23/08/2018

**Last updated:** 30/01/2020

[View](/en/documents/rmp-summary/zelboraf-epar-risk-management-plan-summary_en.pdf)

## Product information

Zelboraf : EPAR - Product Information

English (EN) (443.6 KB - PDF)

**First published:** 19/03/2012

**Last updated:** 19/06/2025

[View](/en/documents/product-information/zelboraf-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-199)

български (BG) (500.01 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

19/06/2025

[View](/bg/documents/product-information/zelboraf-epar-product-information_bg.pdf)

español (ES) (342.79 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

19/06/2025

[View](/es/documents/product-information/zelboraf-epar-product-information_es.pdf)

čeština (CS) (446.89 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

19/06/2025

[View](/cs/documents/product-information/zelboraf-epar-product-information_cs.pdf)

dansk (DA) (351.43 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

19/06/2025

[View](/da/documents/product-information/zelboraf-epar-product-information_da.pdf)

Deutsch (DE) (702.46 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

29/07/2025

[View](/de/documents/product-information/zelboraf-epar-product-information_de.pdf)

eesti keel (ET) (324.78 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

19/06/2025

[View](/et/documents/product-information/zelboraf-epar-product-information_et.pdf)

ελληνικά (EL) (538.72 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

19/06/2025

[View](/el/documents/product-information/zelboraf-epar-product-information_el.pdf)

français (FR) (367.79 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

19/06/2025

[View](/fr/documents/product-information/zelboraf-epar-product-information_fr.pdf)

hrvatski (HR) (484.5 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

19/06/2025

[View](/hr/documents/product-information/zelboraf-epar-product-information_hr.pdf)

íslenska (IS) (340.81 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

19/06/2025

[View](/is/documents/product-information/zelboraf-epar-product-information_is.pdf)

italiano (IT) (345.03 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

19/06/2025

[View](/it/documents/product-information/zelboraf-epar-product-information_it.pdf)

latviešu valoda (LV) (572.64 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

19/06/2025

[View](/lv/documents/product-information/zelboraf-epar-product-information_lv.pdf)

lietuvių kalba (LT) (461.32 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

19/06/2025

[View](/lt/documents/product-information/zelboraf-epar-product-information_lt.pdf)

magyar (HU) (477.78 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

19/06/2025

[View](/hu/documents/product-information/zelboraf-epar-product-information_hu.pdf)

Malti (MT) (554.34 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

19/06/2025

[View](/mt/documents/product-information/zelboraf-epar-product-information_mt.pdf)

Nederlands (NL) (386.62 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

19/06/2025

[View](/nl/documents/product-information/zelboraf-epar-product-information_nl.pdf)

norsk (NO) (469.88 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

19/06/2025

[View](/no/documents/product-information/zelboraf-epar-product-information_no.pdf)

polski (PL) (491.48 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

19/06/2025

[View](/pl/documents/product-information/zelboraf-epar-product-information_pl.pdf)

português (PT) (396.29 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

19/06/2025

[View](/pt/documents/product-information/zelboraf-epar-product-information_pt.pdf)

română (RO) (496.54 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

19/06/2025

[View](/ro/documents/product-information/zelboraf-epar-product-information_ro.pdf)

slovenčina (SK) (448.03 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

19/06/2025

[View](/sk/documents/product-information/zelboraf-epar-product-information_sk.pdf)

slovenščina (SL) (422.25 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

19/06/2025

[View](/sl/documents/product-information/zelboraf-epar-product-information_sl.pdf)

Suomi (FI) (349.6 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

19/06/2025

[View](/fi/documents/product-information/zelboraf-epar-product-information_fi.pdf)

svenska (SV) (315.04 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

19/06/2025

[View](/sv/documents/product-information/zelboraf-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000279644 19/06/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Zelboraf : EPAR - All Authorised presentations

English (EN) (11.52 KB - PDF)

**First published:** 19/03/2012

**Last updated:** 27/06/2013

[View](/en/documents/all-authorised-presentations/zelboraf-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-515)

български (BG) (38.78 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

27/06/2013

[View](/bg/documents/all-authorised-presentations/zelboraf-epar-all-authorised-presentations_bg.pdf)

español (ES) (13.3 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

27/06/2013

[View](/es/documents/all-authorised-presentations/zelboraf-epar-all-authorised-presentations_es.pdf)

čeština (CS) (23.68 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

27/06/2013

[View](/cs/documents/all-authorised-presentations/zelboraf-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (12.93 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

27/06/2013

[View](/da/documents/all-authorised-presentations/zelboraf-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (12.99 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

27/06/2013

[View](/de/documents/all-authorised-presentations/zelboraf-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (12.96 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

27/06/2013

[View](/et/documents/all-authorised-presentations/zelboraf-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (38.41 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

27/06/2013

[View](/el/documents/all-authorised-presentations/zelboraf-epar-all-authorised-presentations_el.pdf)

français (FR) (12.22 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

27/06/2013

[View](/fr/documents/all-authorised-presentations/zelboraf-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (27.79 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

27/06/2013

[View](/hr/documents/all-authorised-presentations/zelboraf-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (10.56 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

27/06/2013

[View](/is/documents/all-authorised-presentations/zelboraf-epar-all-authorised-presentations_is.pdf)

italiano (IT) (10.17 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

27/06/2013

[View](/it/documents/all-authorised-presentations/zelboraf-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (37.44 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

27/06/2013

[View](/lv/documents/all-authorised-presentations/zelboraf-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (36.92 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

27/06/2013

[View](/lt/documents/all-authorised-presentations/zelboraf-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (39.75 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

27/06/2013

[View](/hu/documents/all-authorised-presentations/zelboraf-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (36.89 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

27/06/2013

[View](/mt/documents/all-authorised-presentations/zelboraf-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (12.31 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

27/06/2013

[View](/nl/documents/all-authorised-presentations/zelboraf-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (12.78 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

27/06/2013

[View](/no/documents/all-authorised-presentations/zelboraf-epar-all-authorised-presentations_no.pdf)

polski (PL) (26.36 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

27/06/2013

[View](/pl/documents/all-authorised-presentations/zelboraf-epar-all-authorised-presentations_pl.pdf)

português (PT) (12.7 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

27/06/2013

[View](/pt/documents/all-authorised-presentations/zelboraf-epar-all-authorised-presentations_pt.pdf)

română (RO) (39.18 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

27/06/2013

[View](/ro/documents/all-authorised-presentations/zelboraf-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (25.89 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

27/06/2013

[View](/sk/documents/all-authorised-presentations/zelboraf-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (10.54 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

27/06/2013

[View](/sl/documents/all-authorised-presentations/zelboraf-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (12.49 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

27/06/2013

[View](/fi/documents/all-authorised-presentations/zelboraf-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (12.68 KB - PDF)

**First published:**

19/03/2012

**Last updated:**

27/06/2013

[View](/sv/documents/all-authorised-presentations/zelboraf-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Zelboraf Active substance vemurafenib International non-proprietary name (INN) or common name vemurafenib Therapeutic area (MeSH) Melanoma Anatomical therapeutic chemical (ATC) code L01EC01

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic melanoma.

## Authorisation details

EMA product number EMEA/H/C/002409 Marketing authorisation holder

Roche Registration GmbH

Emil-Barell-Strasse 1

Opinion adopted 15/12/2011 Marketing authorisation issued 17/02/2012 Revision 26

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Zelboraf : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (245.3 KB - PDF)

**First published:** 19/06/2025

[View](/en/documents/procedural-steps-after/zelboraf-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Zelboraf : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (305.87 KB - PDF)

**First published:** 25/01/2013

**Last updated:** 19/06/2025

[View](/en/documents/procedural-steps-after/zelboraf-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Zelboraf-H-C-PSUSA-9329-202208 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/327031/2023

English (EN) (127.51 KB - PDF)

**First published:** 18/07/2023

[View](/en/documents/scientific-conclusion/zelboraf-h-c-psusa-9329-202208-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Zelboraf-H-C-PSUSA-9329-201608 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/252348/2017

English (EN) (65.22 KB - PDF)

**First published:** 30/05/2017

**Last updated:** 30/05/2017

[View](/en/documents/scientific-conclusion/zelboraf-h-c-psusa-9329-201608-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Zelboraf-H-C-2409-P46-033 : EPAR - Assessment Report

Reference Number: EMA/174418/2017

English (EN) (191.42 KB - PDF)

**First published:** 15/03/2017

**Last updated:** 15/03/2017

[View](/en/documents/variation-report/zelboraf-h-c-2409-p46-033-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Zelboraf : EPAR - Public assessment report

Reference Number: EMA/200986/2012

English (EN) (1.81 MB - PDF)

**First published:** 19/03/2012

**Last updated:** 19/03/2012

[View](/en/documents/assessment-report/zelboraf-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Zelboraf

Adopted

Reference Number: EMA/CHMP/926998/2011

English (EN) (45.29 KB - PDF)

**First published:** 16/12/2011

**Last updated:** 16/12/2011

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-zelboraf_en.pdf)

#### News on Zelboraf

[European Medicines Agency finalises review of medicines concerned by Roche pharmacovigilance inspection](/en/news/european-medicines-agency-finalises-review-medicines-concerned-roche-pharmacovigilance-inspection) 19/11/2013

[European Medicines Agency starts infringement procedure to investigate Roche's alleged non-compliance with pharmacovigilance obligations](/en/news/european-medicines-agency-starts-infringement-procedure-investigate-roches-alleged-non-compliance-pharmacovigilance-obligations) 23/10/2012

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Zelboraf : EPAR - Product information - tracked changes

English (EN) (212.08 KB - DOCX)

**First published:** 19/06/2025

[View](/en/documents/product-information-tracked-changes/zelboraf-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-250)

български (BG) (258.34 KB - DOCX)

**First published:**

19/06/2025

[View](/bg/documents/product-information-tracked-changes/zelboraf-epar-product-information-tracked-changes_bg.docx)

español (ES) (177.98 KB - DOCX)

**First published:**

19/06/2025

[View](/es/documents/product-information-tracked-changes/zelboraf-epar-product-information-tracked-changes_es.docx)

čeština (CS) (184.56 KB - DOCX)

**First published:**

19/06/2025

[View](/cs/documents/product-information-tracked-changes/zelboraf-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (224.75 KB - DOCX)

**First published:**

19/06/2025

[View](/da/documents/product-information-tracked-changes/zelboraf-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (343.52 KB - DOCX)

**First published:**

19/06/2025

**Last updated:**

29/07/2025

[View](/de/documents/product-information-tracked-changes/zelboraf-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (171.38 KB - DOCX)

**First published:**

19/06/2025

[View](/et/documents/product-information-tracked-changes/zelboraf-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (190.07 KB - DOCX)

**First published:**

19/06/2025

[View](/el/documents/product-information-tracked-changes/zelboraf-epar-product-information-tracked-changes_el.docx)

français (FR) (196.86 KB - DOCX)

**First published:**

19/06/2025

[View](/fr/documents/product-information-tracked-changes/zelboraf-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (235.59 KB - DOCX)

**First published:**

19/06/2025

[View](/hr/documents/product-information-tracked-changes/zelboraf-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (167.22 KB - DOCX)

**First published:**

19/06/2025

[View](/is/documents/product-information-tracked-changes/zelboraf-epar-product-information-tracked-changes_is.docx)

italiano (IT) (189.98 KB - DOCX)

**First published:**

19/06/2025

[View](/it/documents/product-information-tracked-changes/zelboraf-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (199.29 KB - DOCX)

**First published:**

19/06/2025

[View](/lv/documents/product-information-tracked-changes/zelboraf-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (221.06 KB - DOCX)

**First published:**

19/06/2025

[View](/lt/documents/product-information-tracked-changes/zelboraf-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (280.52 KB - DOCX)

**First published:**

19/06/2025

[View](/hu/documents/product-information-tracked-changes/zelboraf-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (2.13 MB - DOCX)

**First published:**

19/06/2025

[View](/mt/documents/product-information-tracked-changes/zelboraf-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (265.96 KB - DOCX)

**First published:**

19/06/2025

[View](/nl/documents/product-information-tracked-changes/zelboraf-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (205.88 KB - DOCX)

**First published:**

19/06/2025

[View](/no/documents/product-information-tracked-changes/zelboraf-epar-product-information-tracked-changes_no.docx)

polski (PL) (228.25 KB - DOCX)

**First published:**

19/06/2025

[View](/pl/documents/product-information-tracked-changes/zelboraf-epar-product-information-tracked-changes_pl.docx)

português (PT) (218.9 KB - DOCX)

**First published:**

19/06/2025

[View](/pt/documents/product-information-tracked-changes/zelboraf-epar-product-information-tracked-changes_pt.docx)

română (RO) (235.24 KB - DOCX)

**First published:**

19/06/2025

[View](/ro/documents/product-information-tracked-changes/zelboraf-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (212.61 KB - DOCX)

**First published:**

19/06/2025

[View](/sk/documents/product-information-tracked-changes/zelboraf-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (179.47 KB - DOCX)

**First published:**

19/06/2025

[View](/sl/documents/product-information-tracked-changes/zelboraf-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (195.7 KB - DOCX)

**First published:**

19/06/2025

[View](/fi/documents/product-information-tracked-changes/zelboraf-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (195.27 KB - DOCX)

**First published:**

19/06/2025

[View](/sv/documents/product-information-tracked-changes/zelboraf-epar-product-information-tracked-changes_sv.docx)

#### More information on Zelboraf

- [The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use](http://www.ejcancer.com/article/S0959-8049(13)00077-4/abstract)

#### More information on Zelboraf

- [EMEA-000978-PIP01-10-M01 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000978-pip01-10-m01)
- [ZeSS: A Prospective Observational Safety Study of Patients with BRAFV600 Mutation-positive Unresectable or Metastatic Melanoma Treated with Vemurafenib (Zelboraf®) - post-authorisation study](https://catalogues.ema.europa.eu/study/21125)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 19/06/2025

## Share this page

[Back to top](#main-content)